Massive human-chain formed in Tirunelveli to combat drug abuse, alcoholism, and communal disharmony.
ByAinvest
Wednesday, Aug 13, 2025 12:32 pm ET1min read
LLY--
Mounjaro Kwikpen is available in six dose strengths ranging from 2.5 mg to 15 mg, with pricing varying from 14,000 to 27,500 rupees per month. The smallest doses are priced at 14,000 rupees and 17,500 rupees, while the 7.5 mg and 10 mg doses cost 22,000 rupees. The 12.5 mg and 15 mg doses are priced at 27,500 rupees [1].
Novo Nordisk's Wegovy, also a GLP-1 receptor agonist, has smaller doses ranging from 0.25 mg to 2.4 mg, priced between 17,345 to 26,015 rupees per month. The highest doses of Mounjaro are priced more competitively compared to Wegovy [1].
Lilly began selling Mounjaro in India in late March for diabetes and obesity management in 2.5 mg and 5 mg vials. Both drugs have seen strong demand since their launch, with sales in July doubling month-on-month [1].
The human-chain organized by the Forum for Social Harmony in Tirunelveli, India, aimed to raise awareness about drug abuse, alcoholism, and communal disharmony. The event, which saw participation from over 3,000 students and activists, was inaugurated by Assistant Collector Dhawlendu [2].
References:
[1] https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-launches-mounjaro-pen-india-160-starting-dose-stepping-up-novo-rivalry-2025-08-13/
[2] https://www.thehindu.com/news/cities/Madurai/human-chain-against-drug-abuse-alcoholism/article69929982.ece
NVO--
A human-chain was organized by the Forum for Social Harmony in Tirunelveli, India, to raise awareness about drug abuse, alcoholism, and communal disharmony. Over 3,000 students and activists participated in the event, which was inaugurated by Assistant Collector Dhawlendu. The event aimed to foster communal harmony and promote a drug-free and alcohol-free society.
Eli Lilly (LLY.N) has recently launched its Mounjaro Kwikpen, a once-weekly injection device, in India. This move is part of the company's strategy to compete with Novo Nordisk (NOVOb.CO) in the market for weight-loss and diabetes management drugs. The launch follows a similar pen device launch by Novo Nordisk, Wegovy, in India.Mounjaro Kwikpen is available in six dose strengths ranging from 2.5 mg to 15 mg, with pricing varying from 14,000 to 27,500 rupees per month. The smallest doses are priced at 14,000 rupees and 17,500 rupees, while the 7.5 mg and 10 mg doses cost 22,000 rupees. The 12.5 mg and 15 mg doses are priced at 27,500 rupees [1].
Novo Nordisk's Wegovy, also a GLP-1 receptor agonist, has smaller doses ranging from 0.25 mg to 2.4 mg, priced between 17,345 to 26,015 rupees per month. The highest doses of Mounjaro are priced more competitively compared to Wegovy [1].
Lilly began selling Mounjaro in India in late March for diabetes and obesity management in 2.5 mg and 5 mg vials. Both drugs have seen strong demand since their launch, with sales in July doubling month-on-month [1].
The human-chain organized by the Forum for Social Harmony in Tirunelveli, India, aimed to raise awareness about drug abuse, alcoholism, and communal disharmony. The event, which saw participation from over 3,000 students and activists, was inaugurated by Assistant Collector Dhawlendu [2].
References:
[1] https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-launches-mounjaro-pen-india-160-starting-dose-stepping-up-novo-rivalry-2025-08-13/
[2] https://www.thehindu.com/news/cities/Madurai/human-chain-against-drug-abuse-alcoholism/article69929982.ece

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet